Richard M Tsai1, Iryna Lobach2, Jee Bang3, Jennifer L Whitwell4, Matthew L Senjem4, Clifford R Jack4, Howard Rosen3, Bruce Miller3, Adam L Boxer3. 1. Memory and Aging Center, University of California at San Francisco, San Francisco, CA, USA. Electronic address: Richard.Tsai@ucsf.edu. 2. Department of Epidemiology and Biostatistics, Division of Biostatistics, University of California at San Francisco, San Francisco, CA, USA. 3. Memory and Aging Center, University of California at San Francisco, San Francisco, CA, USA. 4. Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: There are no effective treatments for progressive supranuclear palsy (PSP). Volumetric MRI (vMRI) may be a useful surrogate outcome measure in PSP clinical trials. The goal of the study was to evaluate the potential of vMRI to correlate with clinical outcomes from an international clinical trial population. METHODS: PSP patients (n = 198) from the AL-108-231 trial who had high quality vMRI and Progressive Supranuclear Palsy Rating Scale (PSPRS), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Schwab and England Activities of Daily Living (SEADL), Color Trails Test, Geriatric Depression Screen (GDS) and one year Clinician Global Impression of Change (CGIC) data from the baseline and 52 week visits were included. Linear regression was used to relate baseline values and annual clinical rating scale changes to annual regional vMRI changes (whole brain, ventricular, midbrain and superior cerebellar peduncle volumes). RESULTS: Effect sizes (Cohen's d) measuring disease progression over one year were largest for vMRI (midbrain [1.27] and ventricular volume [1.31]) but similar to PSPRS (1.26). After multiple comparison adjustment, annual changes in PSPRS, RBANS, SEADL, Color Trails Test, GDS and one year CGIC were modestly correlated with annual vMRI changes (p < 0.05). Baseline neuropsychological status on RBANS (p = 0.019) and Color Trails (p < 0.01) predicted annual midbrain atrophy rates. CONCLUSION: Standard vMRI measurements are sensitive to disease progression in large, multicenter PSP clinical trials, but are not well correlated with clinical changes. vMRI changes may be useful as supportive endpoints in PSP trials. Published by Elsevier Ltd.
INTRODUCTION: There are no effective treatments for progressive supranuclear palsy (PSP). Volumetric MRI (vMRI) may be a useful surrogate outcome measure in PSP clinical trials. The goal of the study was to evaluate the potential of vMRI to correlate with clinical outcomes from an international clinical trial population. METHODS:PSPpatients (n = 198) from the AL-108-231 trial who had high quality vMRI and Progressive Supranuclear Palsy Rating Scale (PSPRS), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Schwab and England Activities of Daily Living (SEADL), Color Trails Test, Geriatric Depression Screen (GDS) and one year Clinician Global Impression of Change (CGIC) data from the baseline and 52 week visits were included. Linear regression was used to relate baseline values and annual clinical rating scale changes to annual regional vMRI changes (whole brain, ventricular, midbrain and superior cerebellar peduncle volumes). RESULTS: Effect sizes (Cohen's d) measuring disease progression over one year were largest for vMRI (midbrain [1.27] and ventricular volume [1.31]) but similar to PSPRS (1.26). After multiple comparison adjustment, annual changes in PSPRS, RBANS, SEADL, Color Trails Test, GDS and one year CGIC were modestly correlated with annual vMRI changes (p < 0.05). Baseline neuropsychological status on RBANS (p = 0.019) and Color Trails (p < 0.01) predicted annual midbrain atrophy rates. CONCLUSION: Standard vMRI measurements are sensitive to disease progression in large, multicenter PSP clinical trials, but are not well correlated with clinical changes. vMRI changes may be useful as supportive endpoints in PSP trials. Published by Elsevier Ltd.
Authors: Hugo Botha; Jennifer L Whitwell; Ajay Madhaven; Matthew L Senjem; Val Lowe; Keith A Josephs Journal: Parkinsonism Relat Disord Date: 2013-11-04 Impact factor: 4.891
Authors: Günter U Höglinger; Hans-Jürgen Huppertz; Stefan Wagenpfeil; María V Andrés; Vincente Belloch; Teresa León; Teodoro Del Ser Journal: Mov Disord Date: 2014-01-31 Impact factor: 10.338
Authors: Adam L Boxer; Michael D Geschwind; Nataliya Belfor; Maria Luisa Gorno-Tempini; Guido F Schauer; Bruce L Miller; Michael W Weiner; Howard J Rosen Journal: Arch Neurol Date: 2006-01
Authors: Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto Journal: Lancet Neurol Date: 2014-05-27 Impact factor: 44.182
Authors: Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind Journal: Semin Neurol Date: 2017-12-05 Impact factor: 3.420
Authors: Hilary W Heuer; P Wang; K Rascovsky; A Wolf; B Appleby; J Bove; Y Bordelon; P Brannelly; D E Brushaber; C Caso; G Coppola; B Dickerson; S Dickinson; K Domoto-Reilly; K Faber; J Ferrall; J Fields; A Fishman; J Fong; T Foroud; L K Forsberg; D Gearhart; B Ghazanfari; N Ghoshal; J Goldman; J Graff-Radford; N Graff-Radford; I Grant; M Grossman; D Haley; G-Y Hsiung; E Huey; D Irwin; D Jones; K Kantarci; A Karydas; D Kaufer; D Kerwin; D Knopman; J Kornak; J H Kramer; R Kraft; W K Kremers; W Kukull; I Litvan; P Ljubenkov; I R Mackenzie; M Maldonado; M Manoochehri; S McGinnis; E McKinley; M F Mendez; B L Miller; C Onyike; A Pantelyat; R Pearlman; L Petrucelli; M Potter; R Rademakers; E M Ramos; K P Rankin; E D Roberson; E Rogalski; P Sengdy; L Shaw; J Syrjanen; M C Tartaglia; N Tatton; J Taylor; A Toga; J Trojanowski; S Weintraub; B Wong; Z Wszolek; B F Boeve; H J Rosen; A L Boxer Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566
Authors: Tien Dam; Adam L Boxer; Lawrence I Golbe; Günter U Höglinger; Huw R Morris; Irene Litvan; Anthony E Lang; Jean-Christophe Corvol; Ikuko Aiba; Michael Grundman; Lili Yang; Beth Tidemann-Miller; Joseph Kupferman; Kristine Harper; Kubra Kamisoglu; Michael J Wald; Danielle L Graham; Liz Gedney; John O'Gorman; Samantha Budd Haeberlein Journal: Nat Med Date: 2021-08-12 Impact factor: 87.241
Authors: Arthur Cassa Macedo; Luciano Inácio Mariano; Marina Isoni Martins; Clarisse Vasconcelos Friedlaender; Jesus Mística Ventura; João Victor de Faria Rocha; Sarah Teixeira Camargos; Francisco Eduardo Costa Cardoso; Paulo Caramelli; Leonardo Cruz de Souza Journal: Mov Disord Clin Pract Date: 2022-04-04
Authors: Günter U Höglinger; Jakob Schöpe; Maria Stamelou; Jan Kassubek; Teodoro Del Ser; Adam L Boxer; Stefan Wagenpfeil; Hans-Jürgen Huppertz Journal: Mov Disord Date: 2017-04-24 Impact factor: 10.338
Authors: Julio C Rojas; Jee Bang; Iryna V Lobach; Richard M Tsai; Gil D Rabinovici; Bruce L Miller; Adam L Boxer Journal: Neurology Date: 2017-12-27 Impact factor: 9.910
Authors: Sanne Simone Kaalund; Luca Passamonti; Kieren S J Allinson; Alexander G Murley; Trevor W Robbins; Maria Grazia Spillantini; James B Rowe Journal: Acta Neuropathol Commun Date: 2020-02-04 Impact factor: 7.801
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Hugo Botha; Farwa Ali; Heather M Clark; Joseph R Duffy; Rene L Utianski; Chase A Stevens; Stephen D Weigand; Christopher G Schwarz; Matthew L Senjem; Clifford R Jack; Val J Lowe; J Eric Ahlskog; Dennis W Dickson; Keith A Josephs Journal: Neuroimage Clin Date: 2019-12-28 Impact factor: 4.881
Authors: Maura Malpetti; Luca Passamonti; Peter Simon Jones; Duncan Street; Timothy Rittman; Timothy D Fryer; Young T Hong; Patricia Vàsquez Rodriguez; William Richard Bevan-Jones; Franklin I Aigbirhio; John Tiernan O'Brien; James Benedict Rowe Journal: J Neurol Neurosurg Psychiatry Date: 2021-03-17 Impact factor: 13.654